WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Vibrant festival highlights cultural charm of various Chinese ethnic groupsVietnam police arrest assistant to National Assembly chairman — Radio Free AsiaChina urges U.S. to formulate universal data security rules to enable orderly, free data flowsBeijing base to bring in 50 giant pandas in 2025China to raise gasoline, diesel retail pricesIran's president holds talks with Pakistani premier after arrival in Islamabad for a 3China's central bank adds liquidity via reverse reposWith homelessness on the rise, Supreme Court to weigh bans on sleeping outdoorsAustralian woman appears in court charged with poisoning husband and his relatives with mushroomsThe top 10 cities for job hunters revealed